Global Information Inc. would like to present a new market research report, "Hospital Acquired Infections: Testing Markets" by Kalorama Information.
The growing focus on hospital-acquired infections (HAI) as a driver of costs and negative outcomes is increasing demand for diagnostic products that can help hospitals and nursing homes decide which patients need treatment and possible isolation. According to a recent report by healthcare market research publisher Kalorama Information, Hospital-Acquired Infections: Testing Markets, the need to combat HAIs has led to increased sales of IVD products designed to test for the infections, growing 10% in 2011 to reach $1.2 billion.
According to the report, the most common hospital-acquired infections, or nosocomial infections, interfering with treatment include MRSA, tuberculosis and urinary tract infections. With 5% of the nearly 40 million hospital visits a year resulting in a HAI, nearly 100,000 people die each year from nosocomial infections, a fifth of these from MRSA alone. In the ICU, where infection is most harmful due to the compromised status of patients, community-acquired pneumonia is a growing problem.
"Nosocomial infections are a fact of life in healthcare right now - as one infection may decline, a new infection appears or there is an increase in the incidence of another," says Bruce Carlson, publisher of Kalorama Information. "Speed is essential in identifying these infections, and there are a host of tests out there, targeting specific infections and offering fast results."
The simplest test would consist of a nostril swab to detect MRSA and assist in admissions screening to reduce the spread of the disease. Specific to tuberculosis, identifying the M. tuberculosis organism is necessary for diagnosis, and methods include imaging or the Mantoux skin test. The report also details more complicated testing areas including drug resistance/susceptibility testing, DNA sequencing, solid-phase hybridization, microarrays, phage-based assays and many more.
Kalorama Informations report, Hospital-Acquired Infections: Testing Markets, discusses the status of the field of HAI diagnostics as a setting-specific field of application. It reveals developments in this area, provides market size and epidemiological data, and profiles key players. It also gives segmented market data for molecular and conventional testing, covers the development of new testing systems and products and provides an analysis of growing drug resistance.